+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Epidural Abscess Drug"

Epidural Abscess Treatment Global Market Report 2024 - Product Thumbnail Image

Epidural Abscess Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

An epidural abscess is an accumulation of pus between the dura mater and the skull or spine. In the context of central nervous system (CNS) drugs, the treatment for an epidural abscess typically involves a combination of surgical intervention and antibiotic therapy. CNS drugs encompass a wide range of medications designed to alleviate or treat conditions affecting brain and spinal cord function. Specifically for epidural abscesses, antibiotic therapy is a critical component as these infections are often bacterial in origin. The choice of antibiotics depends on the causative organisms, which are determined through clinical evaluation and diagnostic tests. CNS drugs targeting infections are crucial to managing the delicate balance of eradicating the infection without causing further damage to the nervous system. Various pharmaceutical companies participate in the market focusing on drugs related to the CNS and infections. Some of these include Pfizer, which has a range of antibiotic therapies; Merck & Co., known for its antimicrobial products; Roche, which provides a selection of antibiotics, and Teva Pharmaceutical Industries, offering generic versions of CNS drugs. These companies, along with others like Novartis and GlaxoSmithKline, play a role in developing and distributing medications that are used in the treatment of epidural abscesses and other CNS related conditions. Show Less Read more